HeberFERON是治疗基底细胞癌的一个有希望的选择

Integrative cancer science and therapeutics Pub Date : 2018-01-01 DOI:10.15761/ICST.1000292

I. B. Rivero

{"title":"HeberFERON是治疗基底细胞癌的一个有希望的选择","authors":"I. B. Rivero","doi":"10.15761/ICST.1000292","DOIUrl":null,"url":null,"abstract":"In 2005, these efforts were crowned with the presentation of a patent describing the obtaining of a new formulation of IFNs, based on the synergism of the combination of the IFNs alpha 2b and gamma and in an ingenious work of identification of excipients, which allowed to obtain a new formulation of IFNs, unique in the world, with a stronger antitumor action than separately IFNs and more safely, during the treatment of patients [1].","PeriodicalId":90850,"journal":{"name":"Integrative cancer science and therapeutics","volume":"5 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"HeberFERON, a promising choice for the treatment of basal cell carcinoma\",\"authors\":\"I. B. Rivero\",\"doi\":\"10.15761/ICST.1000292\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In 2005, these efforts were crowned with the presentation of a patent describing the obtaining of a new formulation of IFNs, based on the synergism of the combination of the IFNs alpha 2b and gamma and in an ingenious work of identification of excipients, which allowed to obtain a new formulation of IFNs, unique in the world, with a stronger antitumor action than separately IFNs and more safely, during the treatment of patients [1].\",\"PeriodicalId\":90850,\"journal\":{\"name\":\"Integrative cancer science and therapeutics\",\"volume\":\"5 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Integrative cancer science and therapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15761/ICST.1000292\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Integrative cancer science and therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15761/ICST.1000292","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

摘要

2005年，这些努力获得了一项专利，该专利描述了基于IFNs α 2b和γ组合的协同作用以及赋形剂鉴定的巧妙工作，获得了一种新的IFNs配方，这是世界上独一无二的，具有比单独的IFNs更强的抗肿瘤作用，并且在治疗患者bbb期间更安全。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

HeberFERON, a promising choice for the treatment of basal cell carcinoma

In 2005, these efforts were crowned with the presentation of a patent describing the obtaining of a new formulation of IFNs, based on the synergism of the combination of the IFNs alpha 2b and gamma and in an ingenious work of identification of excipients, which allowed to obtain a new formulation of IFNs, unique in the world, with a stronger antitumor action than separately IFNs and more safely, during the treatment of patients [1].

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Integrative cancer science and therapeutics

自引率

0.00%

发文量